Concepts (184)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Anti-HIV Agents | 6 | 2020 | 2209 | 0.74 | Why? |
| Infrared Rays | 1 | 2019 | 127 | 0.73 | Why? |
| Teratogens | 1 | 2017 | 15 | 0.72 | Why? |
| Hepatitis D, Chronic | 1 | 2017 | 16 | 0.70 | Why? |
| HIV Infections | 15 | 2020 | 11620 | 0.64 | Why? |
| Biofilms | 1 | 2019 | 304 | 0.62 | Why? |
| Hepatitis A | 1 | 2017 | 140 | 0.58 | Why? |
| Hepatitis C | 4 | 2018 | 1514 | 0.53 | Why? |
| Drug Interactions | 4 | 2017 | 1653 | 0.53 | Why? |
| Hepatitis E | 1 | 2018 | 319 | 0.51 | Why? |
| Pharmacogenetics | 1 | 2014 | 222 | 0.49 | Why? |
| Ribavirin | 3 | 2017 | 1182 | 0.48 | Why? |
| Pre-Exposure Prophylaxis | 2 | 2020 | 1138 | 0.47 | Why? |
| Liver Cirrhosis | 3 | 2017 | 1810 | 0.41 | Why? |
| Hepacivirus | 3 | 2017 | 1509 | 0.41 | Why? |
| Anemia | 1 | 2017 | 789 | 0.40 | Why? |
| Sexually Transmitted Diseases | 1 | 2018 | 694 | 0.39 | Why? |
| Antigens, Viral | 4 | 2021 | 6298 | 0.38 | Why? |
| HIV-1 | 2 | 2020 | 3365 | 0.35 | Why? |
| Homosexuality, Male | 1 | 2017 | 1158 | 0.35 | Why? |
| Malaria | 1 | 2017 | 1097 | 0.33 | Why? |
| Antiviral Agents | 9 | 2020 | 41703 | 0.30 | Why? |
| Liver Neoplasms | 1 | 2017 | 1666 | 0.28 | Why? |
| Coinfection | 3 | 2020 | 6820 | 0.25 | Why? |
| Acquired Immunodeficiency Syndrome | 2 | 2020 | 533 | 0.25 | Why? |
| Europe | 3 | 2021 | 12702 | 0.23 | Why? |
| Epidemics | 3 | 2018 | 6407 | 0.22 | Why? |
| Disease Management | 1 | 2018 | 6841 | 0.19 | Why? |
| Medication Adherence | 3 | 2018 | 1270 | 0.19 | Why? |
| HIV Protease Inhibitors | 1 | 2002 | 434 | 0.19 | Why? |
| Viral Vaccines | 1 | 2020 | 7560 | 0.19 | Why? |
| Lasers | 1 | 2019 | 132 | 0.19 | Why? |
| Silicon Dioxide | 1 | 2019 | 131 | 0.18 | Why? |
| Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | 1 | 2018 | 14 | 0.18 | Why? |
| Delayed-Action Preparations | 1 | 2020 | 291 | 0.18 | Why? |
| Bacillus anthracis | 1 | 2017 | 42 | 0.18 | Why? |
| Anthrax | 1 | 2017 | 35 | 0.18 | Why? |
| Spain | 10 | 2021 | 15545 | 0.18 | Why? |
| Masks | 2 | 2021 | 8528 | 0.18 | Why? |
| Hepatitis Delta Virus | 1 | 2018 | 54 | 0.18 | Why? |
| Hepatitis D | 1 | 2018 | 48 | 0.17 | Why? |
| Macrocyclic Compounds | 1 | 2017 | 78 | 0.17 | Why? |
| HTLV-I Infections | 1 | 2017 | 54 | 0.17 | Why? |
| HIV | 2 | 2010 | 1116 | 0.16 | Why? |
| HIV-2 | 1 | 2017 | 92 | 0.16 | Why? |
| Skin Diseases, Bacterial | 1 | 2017 | 105 | 0.16 | Why? |
| Genotype | 3 | 2017 | 4697 | 0.16 | Why? |
| Heterocyclic Compounds, 4 or More Rings | 1 | 2017 | 139 | 0.16 | Why? |
| Plasmodium vivax | 1 | 2017 | 154 | 0.15 | Why? |
| Interferon-alpha | 3 | 2017 | 1442 | 0.15 | Why? |
| Ethiopia | 2 | 2017 | 1222 | 0.15 | Why? |
| Hepatitis B virus | 2 | 2020 | 882 | 0.15 | Why? |
| Drug Design | 2 | 2018 | 2627 | 0.14 | Why? |
| Sustained Virologic Response | 1 | 2017 | 378 | 0.14 | Why? |
| Hospitals, Rural | 1 | 2017 | 185 | 0.14 | Why? |
| Tropical Medicine | 1 | 2017 | 237 | 0.14 | Why? |
| Lipopeptides | 1 | 2017 | 229 | 0.14 | Why? |
| Drug Users | 1 | 2018 | 234 | 0.14 | Why? |
| Hospital Administration | 1 | 2021 | 650 | 0.13 | Why? |
| Humans | 36 | 2021 | 930598 | 0.13 | Why? |
| Travel Medicine | 1 | 2017 | 335 | 0.13 | Why? |
| Developed Countries | 1 | 2018 | 500 | 0.13 | Why? |
| Carbamates | 1 | 2017 | 485 | 0.13 | Why? |
| Plasmodium falciparum | 1 | 2017 | 337 | 0.13 | Why? |
| Biological Transport | 1 | 2014 | 290 | 0.13 | Why? |
| Hotlines | 1 | 2017 | 337 | 0.13 | Why? |
| Practice Guidelines as Topic | 1 | 2018 | 15421 | 0.13 | Why? |
| Sofosbuvir | 1 | 2017 | 518 | 0.12 | Why? |
| Hepatitis C, Chronic | 3 | 2017 | 973 | 0.12 | Why? |
| Drug Combinations | 3 | 2017 | 3852 | 0.12 | Why? |
| Pyridines | 1 | 2017 | 680 | 0.11 | Why? |
| Genetic Testing | 1 | 2014 | 395 | 0.11 | Why? |
| Piperidines | 1 | 2017 | 795 | 0.11 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.10 | Why? |
| Phosphoproteins | 1 | 2021 | 4346 | 0.10 | Why? |
| Drug Administration Schedule | 1 | 2017 | 2324 | 0.10 | Why? |
| Hepatitis B, Chronic | 1 | 2017 | 616 | 0.10 | Why? |
| Pandemics | 8 | 2021 | 389249 | 0.10 | Why? |
| Disease Outbreaks | 2 | 2017 | 27595 | 0.10 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.10 | Why? |
| Drug Monitoring | 1 | 2017 | 1408 | 0.09 | Why? |
| Sulfonamides | 1 | 2017 | 1294 | 0.09 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.09 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.09 | Why? |
| Dose-Response Relationship, Drug | 1 | 2017 | 3776 | 0.09 | Why? |
| Ritonavir | 1 | 2002 | 4212 | 0.09 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.08 | Why? |
| Nursing Homes | 2 | 2021 | 4155 | 0.08 | Why? |
| Polymorphism, Genetic | 1 | 2014 | 1074 | 0.08 | Why? |
| Polyethylene Glycols | 2 | 2010 | 574 | 0.08 | Why? |
| Consensus | 1 | 2020 | 6345 | 0.07 | Why? |
| Carrier State | 1 | 2017 | 2100 | 0.07 | Why? |
| Research | 1 | 2018 | 2115 | 0.07 | Why? |
| Nasopharynx | 2 | 2021 | 10224 | 0.07 | Why? |
| Polymerase Chain Reaction | 1 | 2020 | 6740 | 0.07 | Why? |
| Canada | 1 | 2018 | 6018 | 0.07 | Why? |
| Precision Medicine | 1 | 2014 | 1477 | 0.07 | Why? |
| Immunoglobulin M | 1 | 2021 | 9091 | 0.06 | Why? |
| Zika Virus Infection | 1 | 2017 | 1920 | 0.06 | Why? |
| Sensitivity and Specificity | 2 | 2021 | 22971 | 0.06 | Why? |
| Incidence | 3 | 2020 | 25622 | 0.06 | Why? |
| Vaccines | 1 | 2020 | 3692 | 0.05 | Why? |
| Hospitals | 1 | 2021 | 11793 | 0.05 | Why? |
| Health Policy | 1 | 2021 | 6242 | 0.05 | Why? |
| Infant | 3 | 2020 | 30274 | 0.05 | Why? |
| Male | 11 | 2021 | 367725 | 0.05 | Why? |
| Gross Domestic Product | 1 | 2021 | 134 | 0.05 | Why? |
| Salvage Therapy | 1 | 2002 | 417 | 0.05 | Why? |
| Child, Preschool | 3 | 2020 | 36283 | 0.05 | Why? |
| Middle Aged | 8 | 2021 | 270681 | 0.05 | Why? |
| Aminoisobutyric Acids | 1 | 2017 | 31 | 0.04 | Why? |
| Models, Economic | 1 | 2021 | 316 | 0.04 | Why? |
| Lactams, Macrocyclic | 1 | 2017 | 130 | 0.04 | Why? |
| Communicable Disease Control | 3 | 2021 | 29620 | 0.04 | Why? |
| Immunoglobulin G | 1 | 2021 | 21571 | 0.04 | Why? |
| Tablets | 1 | 2017 | 219 | 0.04 | Why? |
| Quinoxalines | 1 | 2017 | 95 | 0.04 | Why? |
| Leucine | 1 | 2017 | 121 | 0.04 | Why? |
| Drug Therapy, Combination | 2 | 2017 | 7268 | 0.04 | Why? |
| Female | 9 | 2021 | 380317 | 0.04 | Why? |
| Liver | 1 | 2010 | 4007 | 0.04 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.04 | Why? |
| Hepatitis B Surface Antigens | 1 | 2017 | 305 | 0.04 | Why? |
| Proline | 1 | 2017 | 345 | 0.04 | Why? |
| Seroepidemiologic Studies | 2 | 2021 | 10017 | 0.04 | Why? |
| Cyclopropanes | 1 | 2017 | 332 | 0.04 | Why? |
| Young Adult | 4 | 2020 | 93724 | 0.04 | Why? |
| Drugs, Investigational | 1 | 2017 | 198 | 0.03 | Why? |
| Child | 3 | 2020 | 70012 | 0.03 | Why? |
| Demography | 1 | 2021 | 1660 | 0.03 | Why? |
| Global Health | 1 | 2018 | 13911 | 0.03 | Why? |
| Aged, 80 and over | 3 | 2021 | 88759 | 0.03 | Why? |
| Cohort Studies | 1 | 2018 | 36005 | 0.03 | Why? |
| Mutation | 1 | 2014 | 12376 | 0.03 | Why? |
| Disease Transmission, Infectious | 1 | 2017 | 9044 | 0.03 | Why? |
| Drug Costs | 1 | 2017 | 313 | 0.03 | Why? |
| Adult | 7 | 2021 | 244371 | 0.03 | Why? |
| AIDS Vaccines | 1 | 2018 | 452 | 0.03 | Why? |
| Adolescent | 3 | 2020 | 86841 | 0.03 | Why? |
| Health Care Costs | 1 | 2021 | 1007 | 0.03 | Why? |
| Portugal | 1 | 2017 | 1265 | 0.03 | Why? |
| Government | 1 | 2021 | 1453 | 0.03 | Why? |
| History, 20th Century | 1 | 2018 | 1282 | 0.03 | Why? |
| Latin America | 1 | 2017 | 1721 | 0.03 | Why? |
| Cost-Benefit Analysis | 1 | 2021 | 2259 | 0.03 | Why? |
| Treatment Outcome | 4 | 2018 | 51732 | 0.03 | Why? |
| Age Distribution | 1 | 2020 | 3567 | 0.03 | Why? |
| History, 21st Century | 1 | 2018 | 1849 | 0.03 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.03 | Why? |
| United States | 1 | 2018 | 46150 | 0.03 | Why? |
| Drug Resistance, Viral | 1 | 2017 | 1083 | 0.03 | Why? |
| Viremia | 1 | 2017 | 1020 | 0.02 | Why? |
| Travel-Related Illness | 1 | 2017 | 1357 | 0.02 | Why? |
| Recombinant Proteins | 2 | 2010 | 3786 | 0.02 | Why? |
| Emigrants and Immigrants | 1 | 2017 | 888 | 0.02 | Why? |
| Drug Delivery Systems | 1 | 2018 | 1365 | 0.02 | Why? |
| Molecular Targeted Therapy | 1 | 2017 | 1579 | 0.02 | Why? |
| Acute Disease | 1 | 2020 | 6029 | 0.02 | Why? |
| Aged | 3 | 2021 | 215776 | 0.02 | Why? |
| Retrospective Studies | 2 | 2017 | 105322 | 0.02 | Why? |
| Emergencies | 1 | 2020 | 4095 | 0.02 | Why? |
| Rural Population | 1 | 2017 | 2408 | 0.02 | Why? |
| Molecular Diagnostic Techniques | 1 | 2021 | 4239 | 0.02 | Why? |
| Saliva | 1 | 2021 | 4679 | 0.02 | Why? |
| Public Health Surveillance | 1 | 2018 | 3129 | 0.02 | Why? |
| Animals | 3 | 2018 | 78931 | 0.02 | Why? |
| Algorithms | 1 | 2020 | 7346 | 0.02 | Why? |
| Drug Discovery | 1 | 2017 | 3092 | 0.02 | Why? |
| Specimen Handling | 1 | 2020 | 6190 | 0.02 | Why? |
| Models, Theoretical | 1 | 2021 | 6659 | 0.01 | Why? |
| Mass Screening | 1 | 2021 | 8005 | 0.01 | Why? |
| Contact Tracing | 1 | 2020 | 8448 | 0.01 | Why? |
| RNA, Viral | 2 | 2010 | 32276 | 0.01 | Why? |
| Disease Progression | 1 | 2018 | 13580 | 0.01 | Why? |
| Physicians | 1 | 2018 | 4214 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2018 | 7330 | 0.01 | Why? |
| Critical Care | 1 | 2021 | 14081 | 0.01 | Why? |
| Viral Load | 1 | 2018 | 15850 | 0.01 | Why? |
| Virus Replication | 1 | 2017 | 14331 | 0.01 | Why? |
| Anti-Bacterial Agents | 1 | 2017 | 10083 | 0.01 | Why? |
| Prevalence | 1 | 2018 | 25773 | 0.01 | Why? |
| Intensive Care Units | 1 | 2021 | 29594 | 0.01 | Why? |
| Time Factors | 1 | 2017 | 31397 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2020 | 48226 | 0.01 | Why? |
Barreiro's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(184)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(88)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_